The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: A randomized, controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 4, 2007, Pages 1305-1310

  Grey, Andrew ^a   Bolland, Mark ^a   Gamble, Greg ^a   Wattie, Diana ^a   Horne, Anne ^a   Davidson, James ^b   Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; PROCOLLAGEN; ROSIGLITAZONE;

AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN EXPERIMENT; LUMBAR SPINE; NORMAL HUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 34147154970     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-2646     Document Type: Article

References (44)

1. Yki-Jarvinen H 2004 Thiazolidinediones. N Engl J Med 351:1106-1118
2. Kendall DM 2006 Thiazolidinediones: the case for early use. Diabetes Care 29:154-157
3. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD 2005 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279-1289
4. Yki-Jarvinen H 2005 The PROactive study: some answers, many questions. Lancet 366:1241-1242
5. Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM, Morris DC 1996 Peroxisome proliferator-activated receptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 50:1087-1094
6. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL 1999 Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. J Cell Biochem 74:357-371
7. Kawaguchi H, Akune T, Yamaguchi M, Ohba S, Ogata N, Chung U-i, Kubota N, Terauchi Y, Kadowaki T, Nakamura K 2005 Distinct effects of PPARγ insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. J Bone Miner Metab 23:275-279
8. Khan E, Abu-Amer Y 2003 Activation of peroxisome proliferator-activated receptor-γ inhibits differentiation of preosteoblasts. J Lab Clin Med 142:29-34
9. Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, Tanaka K, Takeuchi Y 1999 Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 140:5060-5065
10. Mbalaviele G, Abu-Amer Y, Meng A, Jaiswal R, Beck S, Pittenger MF, Thiede MA, Marshak DR 2000 Activation of peroxisome proliferator-activated receptor-γ pathway inhibits osteoclast differentiation. J Biol Chem 275:14388-14393
11. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung U-i, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H 2004 PPAR-γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113:846-855
12. Pei L, Tontonoz P 2004 Fat's loss is bone's gain. J Clin Invest 113:805-806
13. Soroceanu MA, Miao D, Bai X-Y, Su H, Goltzman D, Karaplis AC 2004 Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183:203-216
14. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL 2005 Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146:1226-1235
15. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR 2006 Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349-3354
16. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, Tylavsky FA, de Rekeneire N, Harris TB, Newman AB 2005 Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 165:1612-1617
17. de Liefde II, van der Klift M, de Laet CEDH, van Daele PLA, Hofman A, Pols HAP 2005 Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16:1713-1720
18. Nicodemus KK, Folsom AR 2001 Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24:1192-1197
19. Vestergaard P, Rejnmark L, Mosekilde L 2005 Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48:1292-1299
20. Taylor BC, Schreiner PJ, Stone KL, Fink HA, Cummings SR, Nevitt MC, Bowman PJ, Ensrud KE 2004 Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc 52:1479-1486
21. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Zmuda JM, Bauer DC, Tylavsky FA, de Rekeneire N, Harris TB, Newman AB, Health ABCS 2004 Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: the Health, Aging, and Body Composition Study. J Bone Miner Res 19:1084-1091
22. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL 2006 Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 91:3404-3410
23. Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, Rutland MD, Cundy T 2004 Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 35:224-230
24. Reid IR, Lucas J, Wattie D, Horne A, Bolland M, Gamble GD, Davidson JS, Grey AB 2005 Effects of a β-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 90: 5212-5216
25. Truxillo C, Maximum likelihood parameter estimation with incomplete data. SAS Users Group International Conference, Philadelphia, PA, 2005 (http:// www2.sas.com/proceedings/sugi30/111-30.pdf)
26. Ton FN, Gunawardene SC, Lee H, Neer RM 2005 Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 20:464-470
27. Reid IR 1997 Glucocorticoid osteoporosis - mechanisms and management. Eur J Endocrinol 137:209-217
28. Staels B, Fruchart J-C 2005 Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54:2460-2470
29. Ehrmann DA 2005 Polycystic ovary syndrome. N Engl J Med 352:1223-1236
30. The Dream Trial Investigators 2006 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096-1105
31. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B 2004 Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406
32. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL 2002 Divergent effects of selective peroxisome proliferator-activated receptor-γ2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143:2376-2384
33. Jennermann C, Triantafillou J, Cowan D, Pennink BGA, Connolly KM, Morris DC 1995 Effects of thiazolidinediones on bone turnover in the rat. J Bone Miner Res 10(Suppl 1):S241
34. Syversen U, Bakke I, Aune G, Thommesen L 2003 PPAR-α agonists increase bone mineral density in female rats. J Bone Miner Res 18(Suppl 2):S42
35. Li M, Pan LC, Simmons HA, Li Y, Healy DR, Robinson BS, Ke HZ, Brown TA 2006 Surface-specific effects of a PPAR-γ agonist, darglitazone, on bone in mice. Bone 39:796-806
36. Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B 2006 Netoglitazone is a PPAR-γ ligand with selective effects on bone and fat. Bone 38:74-84
37. Okazaki R, Miura M, Toriumi M, Taguchi M, Hirota Y, Fukumoto S, Fujita T, Tanaka K, Takeuchi A 1999 Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 46:795-801
38. Watanabe S, Takeuchi Y, Fukumoto S, Fujita H, Nakano T, Fujita T 2003 Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab 21:166-171
39. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, for the ADOPT Study Group 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443
40. Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, Grey AB, Broom N, Myers DE, Nicholson GC, Reid IR 2002 Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 175:405-415
41. Cornish J, Callon KE, King AR, Cooper GJS, Reid IR 1998 Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol 38:E694-E699
42. Cornish J, Callon KE, Reid IR 1996 Insulin increases histomorphometric indices of bone formation in vivo. Calcif Tissue Int 59:492-495
43. Justesen J, Mosekilde L, Holmes M, Stenderup K, Gasser J, Mullins JJ, Seckl JR, Kassem M 2004 Mice deficient in 11β-hydroxysteroid dehydrogenase type 1 lack bone marrow adipocytes, but maintain normal bone formation. Endocrinology 145:1916-1925
44. Okazaki R, Totsuka Y, Hamano K, Ajima M, Miura M, Hirota Y, Hata K, Fukumoto S, Matsumoto T 1997 Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab 82:2915-2920